Novartis to pay $178m to Plexxikon over patent infringement case

By NS Healthcare Staff Writer

23 Jul 21

The jury found that the Novartis failed to prove that patents were invalid and concluded that the infringement…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals

By NS Healthcare Staff Writer

22 Jul 21

With the acquisition, AstraZeneca now has an enhanced presence in rare diseases and immunology fields, using Alexion’s complement-biology…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Sanofi to sell eight consumer healthcare brands in Latin America to Hypera Pharma

By NS Healthcare Staff Writer

14 Jul 21

The sale is part of Sanofi’s strategy to simplify its consumer healthcare portfolio and advance its growth

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

US strikes $1.2bn deal for Merck’s investigational Covid-19 drug molnupiravir

By NS Healthcare Staff Writer

10 Jun 21

The US government is committed to buy around 1.7 million courses of molnupiravir upon FDA Emergency Use Authorisation…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

UK watchdog probes AstraZeneca’s $39bn Alexion acquisition

By NS Healthcare Staff Writer

26 May 21

AstraZeneca recently received the US Federal Trade Commission (FTC) approval for the proposed acquisition of Alexion

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Zydus rolls out ADC biosimilar Ujvira to treat breast cancer

By NS Healthcare Staff Writer

25 May 21

Zydus claims that Ujvira is the world’s first biosimilar antibody-drug conjugate of trastuzumab emtansine and will be offered…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

GSK to sell its stake in Innoviva for $392m

By NS Healthcare Staff Writer

21 May 21

GSK and Innoviva have jointly developed Trelegy Ellipta, Relvar Ellipta, and Anoro Ellipta drugs for use in asthma…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Thermo Fisher, UCSF partner on new cell therapy manufacturing facility

By NS Healthcare Staff Writer

20 May 21

The new cGMP facility will be designed to provide an end-to-end solution to advance cell therapy development and…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Athenex to acquire Kuur Therapeutics for $185m

By NS Healthcare Staff Writer

05 May 21

Kuur’s NKT cell platform technology will help Athenex to expand its cell therapy development capabilities

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates

Pfizer acquires antifungal therapies developer Amplyx

By NS Healthcare Staff Writer

29 Apr 21

The acquisition follows Pfizer’s initial equity investment in Amplyx, as part of the antifungal therapies developer's Series C…

PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates